DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Medical Cannabis Workgroup
July 11, 2017

The Boards of Medicine and Osteopathic Medicine work on Emergency Rules to implement Senate bill 8-A (2017) Continue reading


2017 Legislation Impacting Your Profession
June 28, 2017

Click here to view a full list of bill summaries from the 2017 Florida Legislative Session that may impact your profession. Continue reading